Facet Biotech Corporation

Facet Biotech Corporation

Facet Biotech Corporation, a biotechnology company, engages in the identification and development of oncology therapeutics. Its products in development include Daclizumab, a monoclonal antibody in Phase II clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, which is in Phase I/II clinical studies is a chimeric monoclonal antibody that inhibits the functional activity of a protein in activated endothelial cells. The company is also developing Elotuzumab, a monoclonal antibody in Phase I clinical study, which binds to a cell surface glycoprotein that is expressed on myeloma cells and normal human cells; PDL192, a monoclonal antibody in Phase I clinical study, which binds to the tumor necrosis factor-like weak inducer of apoptosis receptor; and PDL241, a monoclonal antibody in the preclinical stage for immunologic diseases. Facet Biotech Corporation has a collaboration agreement with Biogen Idec Inc. The company is headquartered in Redwood City, California.

Contact Details

Office Address

Facet Biotech Corporation
1500 Seaport Blvd.
Redwood City, CA, USA 94063
Phone: (650) 454-1000
Fax: (650) 454-2000

Executives

Chief Exec. Officer

Mr. Faheem Hasnain

Chief Financial Officer

Mr. Andrew L. Guggenhime

Business Reviews for Facet Biotech Corporation

Related Companies